Literature DB >> 23543702

Therapeutic strategies, including a high surgical ligation rate, for patent ductus arteriosus closure in extremely premature infants in a North American centre.

Gregory P Moore1, Sarah L Lawrence, Gyaandeo Maharajh, Amanda Sumner, Isabelle Gaboury, Nick Barrowman, Brigitte Lemyre.   

Abstract

OBJECTIVE: To document the rate of surgical ligation of a patent ductus arteriosus (PDA) in extremely premature infants who had received more than one course of indomethacin. Outcomes were compared among three subgroups (ligation, further indomethacin and no further treatment) of infants who received at least one course of indomethacin, and between two subgroups (one course of indomethacin and more than one course) among infants who underwent ligation. STUDY
DESIGN: A retrospective chart review of all 23 weeks+0 days to 26 weeks+6 days' gestational age infants with a PDA born between 1994 and 2005 was performed. Secondary outcomes were compared among the subgroups.
RESULTS: The final study population consisted of 196 extremely premature infants with a PDA. The rate of surgical ligation in the 88 infants who received more than one course of indomethacin was 64%. The ligation subgroup, in comparison with the no further treatment subgroup, spent a greater median time on mechanical ventilation (39 versus 29 days, P<0.001) and in hospital (115 versus 92 days P=0.002), while trending toward lower mortality (18% versus 40%, P=0.07). The PDA closed following the first course of indomethacin in only 20% of infants.
CONCLUSIONS: A majority of extremely premature infants receiving more than one course of indomethacin underwent surgical ligation. Repeated indomethacin courses were generally well tolerated, but were mostly unsuccessful. Ligation appears to have potential risks and benefits. A randomized trial should be performed after studies define a hemodynamically significant PDA that will result in morbidity and/or mortality unless treated.

Entities:  

Keywords:  Ductus arteriosus, patent; Indomethacin; Infant, premature; Ligation

Year:  2012        PMID: 23543702      PMCID: PMC3381669          DOI: 10.1093/pch/17.4.e26

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  30 in total

Review 1.  Current treatment strategies of symptomatic patent ductus arteriosus.

Authors:  Jennifer Tran Pham; Maria A Carlos
Journal:  J Pediatr Health Care       Date:  2002 Nov-Dec       Impact factor: 1.812

2.  Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less.

Authors:  Josh Koch; Gaynelle Hensley; Lonnie Roy; Shannon Brown; Claudio Ramaciotti; Charles R Rosenfeld
Journal:  Pediatrics       Date:  2006-04       Impact factor: 7.124

3.  Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity.

Authors:  Nancy Chorne; Carol Leonard; Robert Piecuch; Ronald I Clyman
Journal:  Pediatrics       Date:  2007-06       Impact factor: 7.124

4.  Two-sided confidence intervals for the single proportion: comparison of seven methods.

Authors:  R G Newcombe
Journal:  Stat Med       Date:  1998-04-30       Impact factor: 2.373

5.  Early surgical ligation versus a conservative approach for management of patent ductus arteriosus that fails to close after indomethacin treatment.

Authors:  Nami Jhaveri; Anita Moon-Grady; Ronald I Clyman
Journal:  J Pediatr       Date:  2010-09       Impact factor: 4.406

6.  Neurodevelopmental follow-up at 36 months' corrected age of preterm infants treated with prophylactic indomethacin.

Authors:  R J Couser; R E Hoekstra; T B Ferrara; G B Wright; A K Cabalka; J E Connett
Journal:  Arch Pediatr Adolesc Med       Date:  2000-06

7.  Patent ductus arteriosus in very low birthweight infants: complications of pharmacological and surgical treatment.

Authors:  P S Koehne; G Bein; V Alexi-Meskhishvili; Y Weng; C Bührer; M Obladen
Journal:  J Perinat Med       Date:  2001       Impact factor: 1.901

8.  Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome.

Authors:  B Van Overmeire; H Van de Broek; P Van Laer; J Weyler; P Vanhaesebrouck
Journal:  J Pediatr       Date:  2001-02       Impact factor: 4.406

9.  Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial.

Authors:  Kristi L Watterberg; Jeffrey S Gerdes; Cynthia H Cole; Susan W Aucott; Elizabeth H Thilo; Mark C Mammel; Robert J Couser; Jeffery S Garland; Henry J Rozycki; Corinne L Leach; Conra Backstrom; Michele L Shaffer
Journal:  Pediatrics       Date:  2004-12       Impact factor: 7.124

10.  Failure of ductus arteriosus closure is associated with increased mortality in preterm infants.

Authors:  Shahab Noori; Michael McCoy; Philippe Friedlich; Brianna Bright; Venugopal Gottipati; Istvan Seri; Kris Sekar
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

View more
  4 in total

1.  Indomethacin vs ibuprofen: comparison of efficacy in the setting of conservative therapeutic approach.

Authors:  Andra Malikiwi; Charlene Roufaeil; Kenneth Tan; Arvind Sehgal
Journal:  Eur J Pediatr       Date:  2014-10-26       Impact factor: 3.183

2.  Relationship Between Hemodynamically Significant Ductus Arteriosus and Ischemia-Modified Albumin in Premature Infants.

Authors:  Hasan Kahveci; Cüneyt Tayman; Fuat Laloğlu; Nazan Kavas; Murat Ciftel; Osman Yılmaz; Esra Laloğlu; Abdulah Erdil; Hülya Aksoy; Salih Aydemir
Journal:  Indian J Clin Biochem       Date:  2015-09-15

Review 3.  Patent ductus arteriosus ligation and adverse outcomes: causality or bias?

Authors:  Dany E Weisz; Patrick J McNamara
Journal:  J Clin Neonatol       Date:  2014-04

4.  Compatibility of intravenous ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion.

Authors:  Jowell Garcia; Alka Garg; Yunmei Song; Ambados Fotios; Chad Andersen; Sanjay Garg
Journal:  PLoS One       Date:  2018-01-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.